Wayne Kuznar


Authored Items

First-in-Class Sotatercept Improves Hemoglobin Levels in Anemic Patients with Myelofibrosis

Emerging Therapies, Web Exclusives

Atlanta, GA—Sotatercept, an investigational activin receptor IIA ligand trap, when used alone or in combination with ruxolitinib (Jakafi), safely increases hemoglobin levels in patients with myeloproliferative neoplasm–associated myelofibrosis, according to data from a phase 2, investigator-initiated clinical trial, presented at ASH 2017. Ruxolitinib is the only medication approved by the [ Read More ]

CAR T-Cell Immunotherapy Makes Strides in Multiple Myeloma, with Durable Remission

Multiple Myeloma, Web Exclusives

Chicago, IL—The era of immunotherapy in multiple myeloma is near. Two presentations at ASCO 2017 demonstrated that cellular therapy can steer immune reconstitution against multiple myeloma. Edward A. Stadtmauer, MD, Chief, Hematologic Malignancies Section, Abramson Cancer Center, University of Pennsylvania, Philadelphia, reviewed cellular strategies, from vaccine-primed T-cell transfer after autologous [ Read More ]

Precision Medicine and Immunotherapy Highlighted at ASH 2017

ASH Highlights, Conference Correspondent, Web Exclusives

Atlanta, GA—More than 25,000 attendees converged on Atlanta during the middle of a rare winter snowstorm to attend ASH 2017, which featured nearly 5000 scientific abstract presentations ranging from cutting-edge advances in gene therapy and personalized medicine to practice-changing discoveries in immunotherapies. Featured topics included the use of combination therapies [ Read More ]

Can Metastatic Cancer with Diagnostic Ambiguity Be Treated Based on Mutational Status Alone?

Uncategorized

The application of molecularly targeted cancer therapies has rapidly expanded in the past 2 decades. The identification of genetic mutations in tumors has led to a growing list of therapies developed to specifically target those alterations. Indeed, molecularly targeted therapies—along with predictive biomarker testing and site-specific chemotherapy—have significantly improved the [ Read More ]

Sign me up!